ArticleEuropean journal of nuclear medicine and molecular imaging2020
Radioembolization of hepatocarcinoma with
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.European journal of nuclear medicine and molecular imaging · 2022Guideline
- Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients.European journal of nuclear medicine and molecular imaging · 2026Article
- Toward Digital Twins for Optimal Radioembolization.PET clinics · 2026Review
- Radioembolization of hepatocellular carcinoma withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective.Korean journal of radiology · 2025Review
- Is there any effect of hcc location on selective internal radiation therapy withAnnals of nuclear medicine · 2025Article
- Utility of pre-procedural [European journal of nuclear medicine and molecular imaging · 2025Observational
- Treatments and cancer: implications for radiologists.Frontiers in immunology · 2025Review
- The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [European journal of nuclear medicine and molecular imaging · 2024Observational
- PET/CT-Based Absorbed Dose Maps inJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Dose-effect relationships in neuroendocrine tumour liver metastases treated with [European journal of nuclear medicine and molecular imaging · 2024Article
- Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.European journal of nuclear medicine and molecular imaging · 2024Article
- Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips.Seminars in interventional radiology · 2024Review
- Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma.European journal of nuclear medicine and molecular imaging · 2023Article
- Predictive Value of [Diagnostics (Basel, Switzerland) · 2023Article
- Automatic healthy liver segmentation for holmium-166 radioembolization dosimetry.EJNMMI research · 2023Article
- Predictive value ofEJNMMI research · 2023Article
- Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.Cardiovascular and interventional radiology · 2023Observational
- A Theranostic Approach in SIRT: Value of Pre-Therapy Imaging in Treatment Planning.Journal of clinical medicine · 2022Review
- A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study.European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
aimTransarterial radioembolization (TARE) is, by all standards, a radiation therapy. As such, according to Euratom Directive 2013/59, it should be optimized by a thorough treatment plan based on the distinct evaluation of absorbed dose to the lesions and to the non-tumoural liver (two-compartment dosimetry). Since the dosimetric prediction with
methodsData from intermediate/advanced hepato-cellular carcinoma (HCC) patients treated with
resultsA 6-month timeline was defined as necessary to capture all treatment-related toxicity events. Previous transarterial chemoembolization (TACE), presence or extension of portal vein tumoural thrombosis (PVTT) and tumour pattern (nodular versus infiltrative) were not associated with tolerance to TARE. On the contrary, at the multivariate analysis, the absorbed dose averaged over the whole non-tumoural liver (including the non-injected lobe) was a prognostic indicator correlated with liver decompensation (odds ratio = 4.24). Basal bilirubin > 1.1 mg/dL was a second even more significant risk factor (odds ratio = 6.35). NTCP analysis stratified with this bilirubin cut-off determined a 15% liver decompensation risk at 50 Gy/90 Gy for bilirubin >/< 1.1 mg/dL. These results are valid for a
conclusionGiven the low predictive accuracy of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.